Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release systems deliver drugs at a controlled rate over extended periods, maintaining steady plasma concentrations. This approach minimizes fluctuations that occur with conventional dosing, enhancing therapeutic effectiveness and reducing the need for frequent dosing. By modulating release rates, these systems improve clinical outcomes in chronic disease management.

Continuous-transit systems include hydrophilic or hydrophobic matrices, reservoir-type systems, osmotic pumps like OROS, and ion-exchange resins. Hydrophilic matrices swell upon contact with gastrointestinal fluids, forming a gel barrier that modulates drug diffusion. These mechanisms allow drugs to pass through the GI tract while gradually releasing the active ingredient.

Osmotic pump systems use osmotic pressure to drive controlled drug release through a semipermeable membrane. Procardia XL releases nifedipine over 24 hours using this mechanism, maintaining consistent therapeutic levels. The semipermeable membrane allows water to enter the tablet, creating pressure that pushes the drug out at a predictable rate.

Gastroretentive systems employ buoyant formulations that float on gastric fluids, mucoadhesive polymers that adhere to the stomach lining, or high-density tablets that resist gastric emptying. The Madopar HBS capsule uses a floating mechanism to deliver levodopa and benserazide gradually, optimizing therapeutic outcomes for Parkinson's disease by maintaining consistent drug concentrations.

Continuous-release formulations improve patient adherence by reducing dosing frequency and minimize side effects associated with peak-trough plasma fluctuations. These systems ensure consistent drug levels, which is critical for managing chronic conditions like Parkinsonism, diabetes, and hypertension. Stable drug exposure enhances clinical efficacy while reducing the burden on patients.

Hydrophilic matrix systems like Wellbutrin XL swell upon contact with gastrointestinal fluids, forming a gel barrier that controls the rate of drug diffusion. As the matrix hydrates, the drug dissolves and diffuses through the gel layer at a controlled pace. This mechanism allows bupropion and other drugs to be released gradually throughout the GI tract.

Gastroretentive systems extend residence time in the stomach, maximizing absorption for drugs that are absorbed primarily in the upper GI tract or degrade in the intestine. By keeping the dosage form in the stomach longer, these systems increase bioavailability and therapeutic effectiveness. This is especially valuable for drugs like levodopa that require specific absorption conditions.